The Committee for Medicinal Products for Human Use, or CHMP, of the EMA adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Doptelet, intended for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. The applicant for this medicinal product is Dova Pharmaceuticals Ireland Limited.
https://thefly.com/landingPageNews.php?id=2898573
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.